Items Tagged ‘precision cancer immunotherapy’

May 11th, 2017

FDA Approval Suggests Keytruda® Combined With Chemotherapy May Become New Standard Initial Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 precision cancer medicine, in combination with Alimta®  (pemetrexed) and carboplatin chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for […]

View full entry

Tags: keytruda, Lung Cancer, News, nsclc, PD-1, precision cancer immunotherapy